Role of Proteolysis in Polyglutamine Disorders

Journal of Neuroscience Research

Volumn 74, Issue 3, 2003, Pages 406-416

  Tarlac, V ^a   Storey, Elsdon ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

Caspase; Huntington's disease; Proteasome; Spinocerebellar ataxias; Triplet repeat disorders

Indexed keywords

ALPHA1A CALCIUM CHANNEL PROTEIN; ANDROGEN RECEPTOR; ATAXIN 1; ATAXIN 2; ATAXIN 3; ATROPHIN 1; CASPASE; GENE PRODUCT; HUNTINGTIN; POLYGLUTAMINE; TATA BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; DEGENERATIVE DISEASE; DENTATORUBROPALLIDOLUYSIAN ATROPHY; ENZYME ACTIVATION; HUMAN; HUNTINGTON CHOREA; KENNEDY DISEASE; MOUSE; NERVE CELL LESION; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; POLYGLUTAMINE DISORDER; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SPINOCEREBELLAR DEGENERATION;

ANIMALS; HUMANS; HUNTINGTON DISEASE; MICE; MULTIENZYME COMPLEXES; MUSCULAR DISORDERS, ATROPHIC; PEPTIDES; SPINOCEREBELLAR ATAXIAS; TRINUCLEOTIDE REPEATS;

EID: 0242361780     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.10746     Document Type: Article

References (132)

1. Auerbach W, Hurlbert MS, Hilditch-Maguire P, Wadghiri YZ, Wheeler VC, Cohen SI, Joyner AL, MacDonald ME, Turnbull DH. 2001. The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. Hum Mol Genet 10:2515-2523.
2. Bailey CK, Andriola IF, Kampinga HH, Merry DE. 2002. Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. Hum Mol Genet 11:515-523.
3. Becher MW, Kotzuk JA, Sharp AH, Davies SW, Bates GP, Price DL, Ross CA. 1998. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat number. Neurobiol Dis 4:387-397.
4. Bence NF, Sampat RM, Kopito RR. 2001. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292:1552-1555.
5. Boutell JM, Thomas P, Neal JW, Weston VJ, Duce J, Harper PS, Jones AL. 1999. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum Mol Genet 8:1647-1655.
6. Brooks BP, Paulson HL, Merry DE, Salazar-Grueso EF, Brinkmann AO, Wilson EM, Fischbeck KH. 1997. Characterization of an expanded glutamine repeat androgen receptor in a neuronal cell culture system. Neurobiol Dis 3:313-323.
7. Butler R, Leigh PN, McPhaul MJ, Gallo JM. 1998. Truncated forms of the androgen receptor are associated with polyglutamine expansion in X-linked spinal and bulbar muscular atrophy. Hum Mol Genet 7:121-127.
8. Chai Y, Shao J, Miller VM, Williams A, Paulson HL. 2002. Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis. Proc Natl Acad Sci USA 99:9310-9315.
9. Chai YH, Koppenhafer SL, Shoesmith SJ, Perez MK, Paulson HL. 1999. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum Mol Genet 8:673-682.
10. Chan SL, Mattson MP. 1999. Caspase and calpain substrates: roles in synaptic plasticity and cell death. J Neurosci Res 58:167-190.
11. Chan HY, Warrick JM, Gray-Board GL, Paulson HL, Bonini NM. 2000. Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila. Hum Mol Genet 9:2811-2820.
12. Chen S, Berthelier V, Yang W, Wetzel R. 2001. Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J Mol Biol 311:173-182.
13. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM. 2000. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6:797-801.
14. Chuang JZ, Zhou H, Zhu M, Li SH, Li XJ, Sung CH. 2002. Characterization of a brain-enriched chaperone, MRJ, that inhibits Huntingtin aggregation and toxicity independently. J Biol Chem 277:19831-19838.
15. Cooper JK, Schilling G, Peters MF, Herring WJ, Sharp AH, Kaminsky Z, Masone J, Khan FA, Delanoy M, Borchelt DR, Dawson VL, Dawson TM, Ross CA. 1998. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet 7:783-790.
16. Cummings CJ, Mancini MA, Antalffy B, DeFranco DB, Orr HT, Zoghbi HY. 1998. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat Genet 19:148-154.
17. Cummings CJ, Reinstein E, Sun Y, Antalffy B, Jiang Y, Ciechanover A, Orr HT, Beaudet AL, Zoghbi HY. 1999. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 24:879-892.
18. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N. 1997. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990-1993.
19. Duyckaerts C, Durr A, Cancel G, Brice A. 1999. Nuclear inclusions in spinocerebellar ataxia type 1. Acta Neuropathol (Berl) 97:201-207.
20. Dyer RB, McMurray CT. 2001. Mutant protein in Huntington disease is resistant to proteolysis in affected brain. Nat Genet 29:270-278.
21. Ellerby LM, Andrusiak RL, Wellington CL, Hackam AS, Propp SS, Wood JD, Sharp AH, Margolis RL, Ross CA, Salvesen GS, Hayden MR, Bredesen DE. 1999a. Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. J Biol Chem 274:8730-8736.
22. Ellerby LM, Hackam AS, Propp SS, Ellerby HM, Rabizadeh S, Cashman NR, Trifiro MA, Pinsky L, Wellington CL, Salvesen GS, Hayden MR, Bredesen DE. 1999b. Kennedy's disease: Caspase cleavage of the androgen receptor is a crucial event in cytotoxicity. J Neurochem 72:185-195.
23. Frontali M. 2001. Spinocerebellar ataxia type 6: channelopathy or glutamine repeat disorder? Brain Res Bull 56:227-231.
24. Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, Richards S, Verkerk AJ, Holden JJ, Fenwick RG Jr, Warren ST, et al. 1991. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 67:1047-1058.
25. Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, Thornberry NA. 1998. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem 273:32608-32613.
26. Garden GA, Libby RT, Fu YH, Kinoshita Y, Huang J, Possin DE, Smith AC, Martinez RA, Fine GC, Grote SK, Ware CB, Einum DD, Morrison RS, Ptacek LJ, Sopher BL, La Spada AR. 2002. Polyglutamine-expanded ataxin-7 promotes non-cell-autonomous purkinje cell degeneration and displays proteolytic cleavage in ataxic transgenic mice. J Neurosci 22:4897-4905.
27. Gervais FG, Singaraja R, Xanthoudakis S, Gutekunst CA, Leavitt BR, Metzler M, Hackam AS, Tam J, Vaillancourt JP, Houtzager V, Rasper DM, Roy S, Hayden MR, Nicholson DW. 2002. Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nat Cell Biol 4:95-105.
28. Goffredo D, Rigamonti D, Tartari M, De Micheli A, Verderio C, Matteoli M, Zuccato C, Cattaneo E. 2002. Calcium-dependent cleavage of endogenous wild-type huntingtin in primary cortical neurons. J Biol Chem 277:39594-39598.
29. Goldberg YP, Nicholson DW, Rasper DM, Kalchman MA, Koide HB, Graham RK, Bromm M, Kazemi-Esfarjani P, Thornberry NA, Vaillancourt JP, Hayden MR. 1996. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet 13:442-449.
30. Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, Rye D, Ferrante RJ, Hersch SM, Li XJ. 1999. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 19:2522-2534.
31. Hackam AS, Yassa AS, Singaraja R, Metzler M, Gutekunst CA, Gan L, Warby S, Wellington CL, Vaillancourt J, Chen NS, Gervais FG, Raymond L, Nicholson DW, Hayden. MR. 2000. Huntingtin interacting protein 1 induces apoptosis via a novel caspase-dependent death effector domain. J Biol Chem 275:41299-41308.
32. Harper JD, Wong SS, Lieber CM, Lansbury PT Jr. 1999. Assembly of Abeta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry 38:8972-8980.
33. Harper PS. 1996. Huntington's disease. London: W.B. Saunders. p 427.
34. Holmberg M, Duyckaerts C, Durr A, Cancel G, Gourfinkel-An I, Damier P, Faucheux B, Trottier Y, Hirsch EC, Agid Y, Brice A. 1998. Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum Mol Genet 7:913-918.
35. Huynh DP, Del Bigio MR, Ho DH, Pulst SM. 1999. Expression of ataxin-2 in brains from normal individuals and patients with Alzheimer's disease and spinocerebellar ataxia 2. Ann Neurol 45:232-241.
36. Huynh DP, Figueroa K, Hoang N, Pulst SM. 2000. Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nat Genet 26:44-50.
37. Ishikawa K, Owada K, Ishida K, Fujigasaki H, Shun Li M, Tsunemi T, Ohkoshi N, Toru S, Mizutani T, Hayashi M, Arai N, Hasegawa K, Kawanami T, Kato T, Makifuchi T, Shoji S, Tanabe T, Mizusawa H. 2001. Cytoplasmic and nuclear polyglutamine aggregates in SCA6 Purkinje cells. Neurology 56:1753-1756.
38. Jana NR, Zemskov EA, Wang GH, Nukina N. 2001. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10:1049-1059.
39. Jonasson J, Strom AL, Hart P, Brannstrom T, Forsgren L, Holmberg M. 2002. Expression of ataxin-7 in CNS and non-CNS tissue of normal and SCA7 individuals. Acta Neuropathol (Berl) 104:29-37.
40. Kalchman MA, Graham RK, Xia G, Koide HB, Hodgson JG, Graham KC, Goldberg YP, Gietz RD, Pickart CM, Hayden MR. 1996. Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J Biol Chem 271:19385-19394.
41. Kaytor MD, Warren ST. 1999. Aberrant protein deposition and neurological disease. J Biol Chem 274:37507-37510.
42. Kegel KB, Kim M, Sapp E, McIntyre C, Castano JG, Aronin N, DiFiglia M. 2000. Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. J Neurosci 20:7268-7278.
43. Kegel KB, Meloni AR, Yi Y, Kim YJ, Doyle E, Cuiffo BG, Sapp E, Wang Y, Qin ZH, Chen JD, Nevins JR, Aronin N, DiFiglia M. 2002. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem 277:7466-7476.
44. Kim M, Lee HS, LaForet G, McIntyre C, Martin EJ, Chang P, Kim TW, Williams M, Reddy PH, Tagle D, Boyce FM, Won L, Heller A, Aronin N, DiFiglia M. 1999. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J Neurosci 19:964-973.
45. Kim YJ, Yi Y, Sapp E, Wang Y, Cuiffo B, Kegel KB, Qin ZH, Aronin N, DiFiglia M. 2001. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc Natl Acad Sci USA 98:12784-12789.
46. Klement IA, Skinner PJ, Kaytor MD, Yi H, Hersch SM, Clark HB, Orr HT. 1998. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95:41-53.
47. Klockgether T. 2000. Clinical approach to ataxic patients. In: Klockgether T, editor. Handbook of ataxia disorders. New York: Marcel Dekker. p 105.
48. Ko J, Ou S, Patterson PH. 2001. New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins. Brain Res Bull 56:319-329.
49. Kobayashi Y, Miwa S, Merry DE, Kume A, Mei L, Doyu M, Sobue G. 1998. Caspase-3 cleaves the expanded androgen receptor protein of spinal and bulbar muscular atrophy in a polyglutamine repeat length-dependent manner. Biochem Biophys Res Commun 252:145-150.
50. Kondo I. 1998. Clinical aspects of DRPLA. In: Warren ST, editor. Genetic instabilities and hereditary neurological diseases. San Diego: Academic Press. p 197-211.
51. Koshy B, Matilla T, Burright EN, Merry DE, Fischbeck KH, Orr HT, Zoghbi HY. 1996. Spinocerebellar ataxia type-1 and spinobulbar muscular atrophy gene products interact with glyceraldehyde-3-phosphate dehydrogenase. Hum Mol Genet 5:1311-1318.
52. Koyano S, Iwabuchi K, Yagishita S, Kuroiwa Y, Uchihara T. 2002. Paradoxical absence of nuclear inclusion in cerebellar Purkinje cells of hereditary ataxias linked to CAG expansion. J Neurol Neurosurg Psychiatry 73:450-452.
53. Kubodera T, Yokota T, Ohwada K, Ishikawa K, Miura H, Matsuoka T, Mizusawa H. 2003. Proteolytic cleavage and cellular toxicity of the human alpha1A calcium channel in spinocerebellar ataxia type 6. Neurosci Lett 341:74-78.
54. Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, Beal MF, Hersch SM, Ferrante RJ. 1999. Huntington aggregates may not predict neuronal death in Huntington's disease. Ann Neurol 46:842-849.
55. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. 1991. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77-79.
56. Li SH, Li XJ. 1998. Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats. Hum Mol Genet 7:777-782.
57. Li H, Li SH, Johnston H, Shelbourne PF, Li XJ. 2000. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat Genet 25:385-389.
58. Li XJ, Li SH, Sharp AH, Nucifora FC, Schilling G, Lanahan A, Worley P, Snyder SH, Ross CA. 1995. A huntingtin-associated protein enriched in brain with implications for pathology. Nature 378:398-402.
59. Li F, Macfarlan T, Pittman RN, Chakravarti D. 2002. Ataxin-3 is a histone binding protein with two independent transcriptional corepressor activities. J Biol Chem 277:45004-45012.
60. Li M, Miwa S, Kobayashi Y, Merry DE, Yamamoto M, Tanaka F, Doyu M, Hashizume Y, Fischbeck KH, Sobue G. 1998a. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann Neurol 44:249-254.
61. Li M, Nakagomi Y, Kobayashi Y, Merry DE, Tanaka F, Doyu M, Mitsuma T, Hashizume Y, Fischbeck KH, Sobue G. 1998b. Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy. Am J Pathol 153:695-701.
62. Lund AH, Mandel JL. 1998. A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum Mol Genet 7:1355-1361.
63. Lunkes A, Lindenberg KS, Ben-Haiem L, Weber C, Devys D, Landwehrmeyer GB, Mandel JL, Trottier Y. 2002. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell 10:259-269.
64. Martin-Aparicio E, Avila J, Lucas JJ. 2002. Nuclear localization of N-terminal mutant huntingtin is cell cycle dependent. Eur J Neurosci 16:355-359.
65. Martindale D, Hackman A, Wieczorek A, Ellerby L, Wellington C, McCutcheon K, Singaraja S, Kazemi-Esfarjani P, Devon R, Kim SU, Bredesen DE, Tufaro F, Hayden MR. 1998. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet 18:150-154.
66. Matilla A, Koshy BT, Cummings CJ, Isobe T, Orr HT, Zoghbi HY. 1997. The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1. Nature 389:974-978.
67. Mazzola JL, Sirover MA. 2002. Alteration of nuclear glyceraldehyde-3-phosphate dehydrogenase structure in Huntington's disease fibroblasts. Brain Res Mol Brain Res 100:95-101.
68. McGowan DP, van Roon-Mom W, Holloway H, Bates GP, Mangiarini L, Cooper GJ, Faull RL, Snell RG. 2000. Amyloid-like inclusions in Huntington's disease. Neuroscience 100:677-680.
69. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. 1999. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46:860-866.
70. Menalled LB, Sison JD, Wu J, Olivieri M, Li XJ, Li H, Zeitlin S, Chesselet MF. 2002. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J Neurosci 22:8266-8276.
71. Mende-Mueller LM, Toneff T, Hwang SR, Chesselet MF, Hook VY. 2001. Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum. J Neurosci 21:1830-1837.
72. Miyashita T, Matsui J, Ohtsuka Y, Mami U, Fujishima S, Okamura-Oho Y, Inoue T, Yamada M. 1999. Expression of extended polyglutamine sequentially activates initiator and effector caspases. Biochem Biophys Res Commun 257:724-730.
73. Miyashita T, Okamura-Oho Y, Mito Y, Nagafuchi S, Yamada M. 1997. Dentatorubral pallidoluysian atrophy (DRPLA) is cleaved by caspase-3 during apoptosis. J Biol Chem 272:29238-29242.
74. Monoi H, Futaki S, Kugimiya S, Minakata H, Yoshihara K. 2000. Poly-L-glutamine forms cation channels: relevance to the pathogenesis of the polyglutamine diseases. Biophys J 78:2892-2899.
75. Mouatt-Prigent A, Karlsson JO, Agid Y, Hirsch EC. 1996. Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? Neuroscience 73:979-987.
76. Munoz E, Rey MJ, Mila M, Cardozo A, Ribalta T, Tolosa E, Ferrer I. 2002. Intranuclear inclusions, neuronal loss and CAG mosaicism in two patients with Machado-Joseph disease. J Neurol Sci 200:19-25.
77. Nakamura K, Jeong SY, Uchihara T, Anno M, Nagashima K, Nagashima T, Ikeda S, Tsuji S, Kanazawa I. 2001. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet 10:1441-1448.
78. Namura S, Hirt L, Wheeler VC, McGinnis KM, Hilditch-Maguire P, Moskowitz MA, MacDonald ME, Persichetti F. 2002. The HD mutation does not alter neuronal death in the striatum of Hdh(Q92) knock-in mice after mild focal ischemia. Neurobiol Dis 11:147-154.
79. Nixon RA, Saito KI, Grynspan F, Griffin WR, Katayama S, Honda T, Mohan PS, Shea TB, Beermann M. 1994. Calcium-activated neuronal proteinase (calpain) system in aging and Alzheimer's disease. Ann N Y Acad Sci 747:77-91.
80. Nucifora FC Jr, Ellerby LM, Wellington CL, Wood JD, Herring WJ, Sawa A, Hayden MR, Dawson VL, Dawson TM, Ross CA. 2003. Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity. J Biol Chem 278:13047-13055.
81. Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM, Frey AS, Menon AS, Li XJ, Stieg PE, Yuan J, Penney JB, Young AB, Cha JH, Friedlander RM. 1999. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399:263-267.
82. Pang JT, Giunti P, Chamberlain S, An SF, Vitaliani R, Scaravilli T, Martinian L, Wood NW, Scaravilli F, Ansorge O. 2002. Neuronal intranuclear inclusions in SCA2: a genetic, morphological and immunohistochemical study of two cases. Brain 125:656-663.
83. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT. 2002. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 5:731-736.
84. Paulson HL, Perez MK, Trottier Y, Trojanowski JQ, Subramony SH, Das SS, Vig P, Mandel JL, Fischbeck KH, Pittman RN. 1997. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19:333-344.
85. Peters MF, Nucifora FC Jr, Kushi J, Seaman HC, Cooper JK, Herring WJ, Dawson VL, Dawson TM, Ross CA. 1999. Nuclear targeting of mutant Huntingtin increases toxicity. Mol Cell Neurosci 14:121-128.
86. Rigamonti D, Bauer JH, De-Fraja C, Conti L, Sipione S, Sciorati C, Clementi E, Hackam A, Hayden MR, Li Y, Cooper JK, Ross CA, Govoni S, Vincenz C, Cattaneo E. 2000. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 20:3705-3713.
87. Rigamonti D, Sipione S, Goffredo D, Zuccato C, Fossale E, Cattaneo E. 2001. Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. J Biol Chem 276:14545-14548.
88. Roy S, Bayly CI, Gareau Y, Houtzager VM, Kargman S, Keen SL, Rowland K, Seiden IM, Thornberry NA, Nicholson DW. 2001. Maintenance of caspase-3 proenzyme dormancy by an intrinsic "safety catch" regulatory tripeptide. Proc Natl Acad Sci USA 98:6132-6137.
89. Sanchez I, Mahlke C, Yuan J. 2003. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421:373-379.
90. Sanchez I, Xu CJ, Juo P, Kakizaka A, Blenis J, Yuan JY. 1999. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 22:623-633.
91. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR. 1999b. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8:397-407.
92. Schilling G, Wood JD, Duan K, Slunt HH, Gonzales V, Yamada M, Cooper JK, Margolis RL, Jenkins NA, Copeland NG, Takahashi H, Tsuji S, Price DL, Borchelt DR, Ross CA. 1999a. Nuclear accumulation of truncated atrophin-1 fragments in a transgenic mouse model of DRPLA. Neuron 24:275-286.
93. Schmidt T, Landwehrmeyer GB, Schmitt I, Trottier Y, Auburger G, Laccone F, Klockgether T, Volpel M, Epplen JT, Schols L, Riess O. 1998. An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol 8:669-679.
94. Schmidt T, Lindenberg KS, Krebs A, Schols L, Laccone F, Herms J, Rechsteiner M, Riess O, Landwehrmeyer GB. 2002. Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions. Ann Neurol 51:302-310.
95. Schotte P, Declercq W, Van Huffel S, Vandenabeele P, Beyaert R. 1999. Non-specific effects of methyl ketone peptide inhibitors of caspases. FEBS Lett 442:117-121.
96. Shang Y, Myers M, Brown M. 2002. Formation of the androgen receptor transcription complex. Mol Cell 9:601-610.
97. Shibata H, Huynh DP, Pulst SM. 2000. A novel protein with RNA-binding motifs interacts with ataxin-2. Hum Mol Genet 9:1303-1313.
98. Sieradzan KA, Mechan AO, Jones L, Wanker EE, Nukina N, Mann DM. 1999. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp Neurol 156:92-99.
99. Simeoni S, Mancini MA, Stenoien DL, Marcelli M, Weigel NL, Zanisi M, Martini L, Poletti A. 2000. Motoneuronal cell death is not correlated with aggregate formation of androgen receptors containing an elongated polyglutamine tract. Hum Mol Genet 9:133-144.
100. Singhrao SK, Thomas P, Wood JD, Macmillan JC, Neal JW, Harper PS, Jones AL. 1998. Huntingtin protein colocalizes with lesions of neurode-generative diseases: an investigation in Huntington's, Alzheimer's, and Pick's diseases. Exp Neurol 150:213-222.
101. Skinner PJ, Koshy BT, Cummings CJ, Klement IA, Helin K, Servadio A, Zoghbi HY, Orr HT. 1997. Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature 389:971-974.
102. Stenoien DL, Cummings CJ, Adams HP, Mancini MG, Patel K, DeMartino GN, Marcelli M, Weigel NL, Mancini MA. 1999. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum Mol Genet 8:731-741.
103. Stenoien DL, Mielke M, Mancini MA. 2002. Intranuclear ataxin1 inclusions contain both fast- and slow-exchanging components. Nat Cell Biol 4:806-810.
104. Storey E. 1998. Dominantly inherited ataxias. Part I. J Clin Neurosci 5:257-264.
105. Suhr ST, Senut MC, Whitelegge JP, Faull KE, Cuizon DB, Gage FH. 2001. Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. J Cell Biol 153:283-294.
106. Sun B, Fan W, Balciunas A, Cooper JK, Bitan G, Steavenson S, Denis PE, Young Y, Adler B, Daugherty L, Manoukian R, Elliott G, Shen W, Talvenheimo J, Teplow DB, Haniu M, Haldankar R, Wypych J, Ross CA, Citron M, Richards WG. 2002. Polyglutamine repeat length-dependent proteolysis of huntingtin. Neurobiol Dis 11:111-122.
107. Tait D, Riccio M, Sittler A, Scherzinger E, Santi S, Ognibene A, Maraldi NM, Lehrach H, Wanker EE. 1998. Ataxin-3 is transported into the nucleus and associates with the nuclear matrix. Hum Mol Genet 7:991-997.
108. Tao T, Tartakoff AM. 2001. Nuclear relocation of normal huntingtin. Traffic 2:385-394.
109. Thornberry NA, Lazebnik Y. 1998. Caspases: enemies within. Science 281:1312-1316.
110. Toneff T, Mende-Mueller L, Wu Y, Hwang SR, Bundey R, Thompson LM, Chesselet MF, Hook V. 2002. Comparison of huntingtin proteolytic fragments in human lymphoblast cell lines and human brain. J Neurochem 82:84-92.
111. Trottier Y, Lutz Y, Stevanin G, Imbert G, Devys D, Cancel G, Saudou F, Weber C, David G, Tora L, Agid Y, Brice A, Mandel JL. 1995. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 378:403-405.
112. Varshavsky A. 1997. The ubiquitin system. Trends Biochem Sci 22:383-387.
113. Verhoef LG, Lindsten K, Masucci MG, Dantuma NP. 2002. Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Hum Mol Genet 11:2689-2700.
114. Vig PJ, Subramony SH, Qin Z, McDaniel DO, Fratkin JD. 2000. Relationship between ataxin-1 nuclear inclusions and Purkinje cell specific proteins in SCA-1 transgenic mice. J Neurol Sci 174:100-110.
115. Villa P, Kaufmann SH, Earnshaw WC. 1997. Caspases and caspase inhibitors. Trends Biochem Sci 22:388-393.
116. Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H, Wanker EE. 2001. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell 12:1393-1407.
117. Wanker EE. 2000. Protein aggregation and pathogenesis of Huntington's disease: mechanism and correlations. Biol Chem 381:937-942.
118. Warrick JM, Chan HY, Gray-Board GL, Chai YH, Paulson HL, Bonini NM. 1999. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet 23:425-428.
119. Warrick JM, Paulson HL, Gray-Board GL, Bui QT, Fischbeck KH, Pittman RN, Bonini NM. 1998. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 93:939-949.
120. Watase K, Weeber EJ, Xu B, Antalffy B, Yuva-Paylor L, Hashimoto K, Kano M, Atkinson R, Sun Y, Armstrong DL, Sweatt JD, Orr HT, Paylor R, Zoghbi HY. 2002. A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron 34:905-919.
121. Wellington CL, Ellerby LM, Gutekunst C-A, Rogers D, Warby S, Graham RK, Loubser O, van Raamsdonk J, Singaraja R, Yang YZ, Gafni J, Bredesen D, Hersch SM, Leavitt BR, Roy S, Nicholson DW, Hayden MR. 2002. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J Neurosci 22:7862-7872.
122. Wellington CL, Ellerby LM, Hackam AS, Margolis RL, Trifiro MA, Singaraja R, McCutcheon K, Salvesen GS, Propp SS, Bromm M, Rowland K, Zhang T, Rasper D, Roy S, Thornberry N, Pinsky L, Kakizuka A, Ross CA, Nicholson DW, Bredesen DE, Hayden MR. 1998. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 273:9158-9167.
123. Wellington CL, Singaraja R, Ellerby L, Savill J, Roy S, Leavitt B, Cattaneo E, Hackam A, Sharp A, Thornberry N, Nicholson DW, Bredesen DE, Hayden MR. 2000. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J Biol Chem 275:19831-19838.
124. Wolf BB, Green DR. 1999. Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem 274:20049-20052.
125. Wyttenbach A, Carmichael J, Swartz J, Furlong RA, Narain Y, Rankin J, Rubinsztein DC. 2000. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci USA 97:2898-2903.
126. Yang W, Dunlap JR, Andrews RB, Wetzel R. 2002. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet 11:2905-2917.
127. Yoo SY, Pennesi ME, Weeber EJ, Xu B, Atkinson R, Chen S, Armstrong DL, Wu SM, Sweatt JD, Zoghbi HY. 2003. SCA7 knockin mice model human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and abnormalities in short-term plasticity. Neuron 37:383-401.
128. Yvert G, Lindenberg KS, Picaud S, Landwehrmeyer GB, Sahel JA, Mandel JL. 2000. Expanded polyglutamines induce neurodegeneration and transneuronal alterations in cerebellum and retina of SCA7 transgenic mice. Hum Mol Genet 9:2491-2506.
129. Zajac JD, MacLean HE. 1998. Kennedy's disease: clinical aspects. In: Warren ST, editor. Genetic instabilities and hereditary neurological diseases. San Diego: Academic Press. p 87-100.
130. Zander C, Takahashi J, El Hachimi KH, Fujigasaki H, Albanese V, Lebre AS, Stevanin G, Duyckaerts C, Brice A. 2001. Similarities between spinocerebellar ataxia type 7 (SCA7) cell models and human brain: proteins recruited in inclusions and activation of caspase-3. Hum Mol Genet 10:2569-2579.
131. Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, Dobyns WB, Subramony SH, Zoghbi HY, Lee CC. 1997. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha(1A0-voltage-dependent calcium channel. Nat Genet 15:62-69.
132. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E. 2001. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293:493-498.